What is LeMaitre Vascular?
LeMaitre Vascular is a vascular surgery devices company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Vascular surgery devices
- Headquarters
- Burlington, MA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: LMAT
What is LeMaitre Vascular?
LeMaitre Vascular is a vascular surgery devices company headquartered in Burlington, MA.
LeMaitre Vascular operates in vascular surgery devices and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around Vascular grafts, Carotid shunts, Valvulotomes, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, LeMaitre Vascular is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: LMAT, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does LeMaitre Vascular offer?
LeMaitre Vascular's profile centers on Vascular grafts, Carotid shunts, Valvulotomes, Patch products.
- Vascular grafts· Vascular surgery devices
- Carotid shunts· Vascular surgery devices
- Valvulotomes· Vascular surgery devices
- Patch products· Vascular surgery devices
- Vascular closure· Vascular surgery devices
- Embolectomy catheters· Vascular surgery devices
How does LeMaitre Vascular make money?
LeMaitre Vascular makes money through commercial activity tied to vascular surgery devices.
LeMaitre Vascular monetizes through the commercial model common to vascular surgery devices: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads LeMaitre Vascular?
LeMaitre Vascular's named executives should be verified on the official leadership or investor-relations page before outreach.
- LeMaitre Vascular executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- LeMaitre Vascular finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- LeMaitre Vascular technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact LeMaitre Vascular's leadership?
LeMaitre Vascular should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.lemaitre.com- LeMaitre Vascular investor relationsInvestor relations / corporate contactcontact via https://www.lemaitre.com
- LeMaitre Vascular media relationsMedia or communications contact routecontact via https://www.lemaitre.com
How is LeMaitre Vascular funded?
LeMaitre Vascular's current status is Public company; Nasdaq: LMAT.
LeMaitre Vascular's current capital profile is best understood through its current status: Public company; Nasdaq: LMAT. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did LeMaitre Vascular get here?
LeMaitre Vascular's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingLeMaitre Vascular is foundedThe company begins building in vascular surgery devices.
- Scale-upCommercial footprint expandsLeMaitre Vascular broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: LMATOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are LeMaitre Vascular's competitors?
LeMaitre Vascular competes with larger platform incumbents and focused specialists in vascular surgery devices.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
LeMaitre Vascular — frequently asked questions
